JP2018534314A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018534314A5 JP2018534314A5 JP2018525730A JP2018525730A JP2018534314A5 JP 2018534314 A5 JP2018534314 A5 JP 2018534314A5 JP 2018525730 A JP2018525730 A JP 2018525730A JP 2018525730 A JP2018525730 A JP 2018525730A JP 2018534314 A5 JP2018534314 A5 JP 2018534314A5
- Authority
- JP
- Japan
- Prior art keywords
- compound according
- heterocycloalkyl
- groups
- alkyl
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 25
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 20
- 125000000217 alkyl group Chemical group 0.000 claims 15
- 239000003814 drug Substances 0.000 claims 10
- -1 NHCO-alkyl Chemical group 0.000 claims 8
- 229940124597 therapeutic agent Drugs 0.000 claims 8
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 claims 7
- 125000003545 alkoxy group Chemical group 0.000 claims 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 230000010261 cell growth Effects 0.000 claims 4
- 125000001188 haloalkyl group Chemical group 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 4
- 208000024827 Alzheimer disease Diseases 0.000 claims 3
- 230000024932 T cell mediated immunity Effects 0.000 claims 3
- 208000034799 Tauopathies Diseases 0.000 claims 3
- 230000001413 cellular effect Effects 0.000 claims 3
- 150000002148 esters Chemical class 0.000 claims 3
- 230000028709 inflammatory response Effects 0.000 claims 3
- 125000002757 morpholinyl group Chemical group 0.000 claims 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims 3
- 125000004193 piperazinyl group Chemical group 0.000 claims 3
- 125000003386 piperidinyl group Chemical group 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 230000004083 survival effect Effects 0.000 claims 3
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 102100030011 Endoribonuclease Human genes 0.000 claims 2
- 101710199605 Endoribonuclease Proteins 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 206010027476 Metastases Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 101710113029 Serine/threonine-protein kinase Proteins 0.000 claims 2
- 125000006580 bicyclic heterocycloalkyl group Chemical group 0.000 claims 2
- 230000004663 cell proliferation Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 230000012010 growth Effects 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 2
- 125000002950 monocyclic group Chemical group 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims 2
- 230000035755 proliferation Effects 0.000 claims 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 2
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 208000002699 Digestive System Neoplasms Diseases 0.000 claims 1
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 claims 1
- 208000009849 Female Genital Neoplasms Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 102000043136 MAP kinase family Human genes 0.000 claims 1
- 108091054455 MAP kinase family Proteins 0.000 claims 1
- 206010059282 Metastases to central nervous system Diseases 0.000 claims 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 1
- 206010029098 Neoplasm skin Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 125000002393 azetidinyl group Chemical group 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 210000000038 chest Anatomy 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 201000011523 endocrine gland cancer Diseases 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 208000037841 lung tumor Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 208000023958 prostate neoplasm Diseases 0.000 claims 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 claims 1
- 201000004477 skin sarcoma Diseases 0.000 claims 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 claims 1
- 208000029584 urinary system neoplasm Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1520500.8A GB201520500D0 (en) | 2015-11-20 | 2015-11-20 | Compounds |
| GB1520500.8 | 2015-11-20 | ||
| PCT/GB2016/053580 WO2017085484A1 (en) | 2015-11-20 | 2016-11-16 | Fused thiazolopyrimidine derivatives as mnks inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021019390A Division JP7181647B2 (ja) | 2015-11-20 | 2021-02-09 | Ｍｎｋ阻害剤としての縮合チアゾロピリミジン誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018534314A JP2018534314A (ja) | 2018-11-22 |
| JP2018534314A5 true JP2018534314A5 (enExample) | 2019-12-26 |
| JP6928605B2 JP6928605B2 (ja) | 2021-09-01 |
Family
ID=55133106
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018525730A Active JP6928605B2 (ja) | 2015-11-20 | 2016-11-16 | Ｍｎｋ阻害剤としての縮合チアゾロピリミジン誘導体 |
| JP2021019390A Active JP7181647B2 (ja) | 2015-11-20 | 2021-02-09 | Ｍｎｋ阻害剤としての縮合チアゾロピリミジン誘導体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021019390A Active JP7181647B2 (ja) | 2015-11-20 | 2021-02-09 | Ｍｎｋ阻害剤としての縮合チアゾロピリミジン誘導体 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US10669284B2 (enExample) |
| EP (2) | EP3939981B1 (enExample) |
| JP (2) | JP6928605B2 (enExample) |
| CN (1) | CN108495855B (enExample) |
| AU (1) | AU2016355104B2 (enExample) |
| CA (2) | CA3240011A1 (enExample) |
| ES (2) | ES2981048T3 (enExample) |
| GB (1) | GB201520500D0 (enExample) |
| WO (1) | WO2017085484A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI713455B (zh) | 2014-06-25 | 2020-12-21 | 美商伊凡克特治療公司 | ＭｎＫ抑制劑及其相關方法 |
| ES2969988T3 (es) | 2017-02-14 | 2024-05-23 | Effector Therapeutics Inc | Inhibidores de Mnk sustituidos con piperidina y métodos relacionados con los mismos |
| CN109020957B (zh) * | 2017-06-12 | 2023-01-13 | 南京天印健华医药科技有限公司 | 作为mnk抑制剂的杂环化合物 |
| WO2020086713A1 (en) | 2018-10-24 | 2020-04-30 | Effector Therapeutics, Inc. | Crystalline forms of mnk inhibitors |
| CN110903286B (zh) * | 2019-12-16 | 2021-09-24 | 沈阳药科大学 | 4,6-双取代吡啶[3,2-d]嘧啶类化合物及其制备和应用 |
| AU2021300363A1 (en) * | 2020-06-30 | 2023-02-09 | 4E Therapeutics, Inc. | Pyridine-1,5-diones exhibiting MNK inhibition and their method of use |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ207394A (en) | 1983-03-08 | 1987-03-06 | Commw Serum Lab Commission | Detecting or determining sequence of amino acids |
| US20050165029A1 (en) * | 2004-01-13 | 2005-07-28 | Ambit Biosciences Corporation | Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases |
| EP1724268A4 (en) | 2004-02-20 | 2010-04-21 | Kirin Pharma Kk | COMPOUNDS WITH TGF-BETA-HEMMENDER EFFECT AND PHARMACEUTICAL COMPOSITION CONTAINING THEM |
| JPWO2005095419A1 (ja) | 2004-04-01 | 2008-02-21 | 武田薬品工業株式会社 | チアゾロピリミジン誘導体 |
| EP1773826A4 (en) | 2004-07-02 | 2009-06-03 | Exelixis Inc | MODULATORS OF C-MET AND THEIR METHOD OF USE |
| US8633201B2 (en) * | 2006-04-07 | 2014-01-21 | Boehringer Ingelheim International Gmbh | Thienopyrimidines having Mnk1/Mnk2 inhibiting activity for pharmaceutical compositions |
| EP1889847A1 (en) * | 2006-07-10 | 2008-02-20 | DeveloGen Aktiengesellschaft | Pyrrolopyrimidines for pharmaceutical compositions |
| WO2008057402A2 (en) * | 2006-11-02 | 2008-05-15 | Cytovia, Inc. | N-aryl-isoxazolopyrimidin-4-amines and related compounds as activators of caspases and inducers of apoptosis and the use thereof |
| EP2219649A2 (en) * | 2007-11-22 | 2010-08-25 | Boehringer Ingelheim International Gmbh | Use of mnk inhibitors for the treatment of alzheimer's disease |
| EP2331551B1 (en) * | 2008-08-26 | 2016-06-29 | Evotec International GmbH | Thienopyrimidines for pharmaceutical compositions |
| UY33241A (es) * | 2010-02-26 | 2011-09-30 | Boehringer Ingelheim Int | ?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?. |
| JP5575274B2 (ja) * | 2010-02-26 | 2014-08-20 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 医薬組成物のためのｍｎｋｌ／ｍｎｋ２阻害活性を有する４−［シクロアルキルオキシ（ヘテロ）アリールアミノ］チエノ「２，３−ｄ］ピリミジン |
| EP2539343B1 (en) * | 2010-02-26 | 2015-12-30 | Evotec International GmbH | Thienopyrimidines containing a substituted alkyl group for pharmaceutical compositions |
| CN102002044A (zh) * | 2010-09-29 | 2011-04-06 | 中国药科大学 | 嘌呤-8-酮类及噻唑并嘧啶类衍生物及其制备方法和医药用途 |
| ES2653419T3 (es) | 2013-02-01 | 2018-02-07 | Bayer Pharma Aktiengesellschaft | Pirazolopirimidinilamino-indazoles sustituidos |
| US9675612B2 (en) | 2013-03-06 | 2017-06-13 | Bayer Pharma Aktiengesellschaft | Substituted thiazolopyrimidines |
| KR20160030239A (ko) * | 2013-07-08 | 2016-03-16 | 바이엘 파마 악티엔게젤샤프트 | 치환된 피라졸로-피리딘아민 |
-
2015
- 2015-11-20 GB GBGB1520500.8A patent/GB201520500D0/en not_active Ceased
-
2016
- 2016-11-16 CA CA3240011A patent/CA3240011A1/en active Pending
- 2016-11-16 ES ES21190890T patent/ES2981048T3/es active Active
- 2016-11-16 EP EP21190890.0A patent/EP3939981B1/en active Active
- 2016-11-16 CN CN201680079581.XA patent/CN108495855B/zh not_active Expired - Fee Related
- 2016-11-16 ES ES16801016T patent/ES2893154T3/es active Active
- 2016-11-16 WO PCT/GB2016/053580 patent/WO2017085484A1/en not_active Ceased
- 2016-11-16 US US15/776,536 patent/US10669284B2/en active Active
- 2016-11-16 JP JP2018525730A patent/JP6928605B2/ja active Active
- 2016-11-16 EP EP16801016.3A patent/EP3377501B1/en active Active
- 2016-11-16 AU AU2016355104A patent/AU2016355104B2/en not_active Ceased
- 2016-11-16 CA CA3003559A patent/CA3003559C/en active Active
-
2020
- 2020-04-22 US US16/855,701 patent/US11136338B2/en not_active Expired - Fee Related
-
2021
- 2021-02-09 JP JP2021019390A patent/JP7181647B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018534314A5 (enExample) | ||
| CN105163584B (zh) | 用于治疗癌症的化合物 | |
| JP2014513110A5 (enExample) | ||
| JP2016530283A5 (enExample) | ||
| JP2014139226A5 (enExample) | ||
| JP2014503567A5 (enExample) | ||
| JP2014518544A5 (enExample) | ||
| CY1124680T1 (el) | Παραγωγα 8-[6-[3-(αμινο)προποξυ]-3-πυριδυλο]-1-ισοπροπυλο-ιμιδαζο[4,5-c]κινολιν-2-ονης ως εκλεκτiκοι ρυθμιστες κινασης μεταλλαγμενης αταξιας τελαγγειεκτασιας (atm) για τη θεραπευτικη αγωγη του καρκινου | |
| JP2018533611A5 (enExample) | ||
| EP3472166A1 (en) | Imidazopyrimidine compounds useful for the treatment of cancer | |
| RU2015124002A (ru) | Соединения, применяемые в качестве ингибиторов индоламин-2,3-диоксигеназы | |
| JP2016525135A5 (enExample) | ||
| JP2016525076A5 (enExample) | ||
| HRP20171248T1 (hr) | Amino-supstituirani imidazopiridazini | |
| JP2014521725A5 (enExample) | ||
| JP2016522232A5 (enExample) | ||
| JP2014505735A5 (enExample) | ||
| RU2018104702A (ru) | Новые соединения пирролопиримидина в качестве ингибиторов протеинкиназ | |
| RU2016134751A (ru) | Соединения | |
| JP2019524883A5 (enExample) | ||
| JP2016523270A5 (enExample) | ||
| JP2014193925A5 (enExample) | ||
| JP2017504635A5 (enExample) | ||
| MX387207B (es) | Inhibidores de proteína quinasa, método de preparación y su uso médico. | |
| JP2017520613A5 (enExample) |